pramipexole
CONCLUSIONS: Subject to the inherent       limitations of modelling chronic disease progression and subsequent healthcare       costs and patient utility, the results suggested that pramipexole was a cost       effective treatment for patients with early and advanced PD in the US.
CONCLUSIONS: Subject to the inherent       limitations of modelling chronic disease progression and subsequent healthcare       costs and patient utility, the results suggested that  @SUBJECT$  @PREDICAT$  @OBJECT$  for patients with early and advanced PD in the US.